


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Cancelled)

2. (Currently Amended) ~~The composition according to claim 1, wherein the compound of formula I is A composition containing 11 β -fluoro-17 β -hydroxy-7 α -methyl-estr-4-en-3-one or a pharmaceutically acceptable salt thereof, and~~



3. (Currently Amended) A pharmaceutical composition containing a composition according to claim 2 ~~claim 1~~ and a pharmaceutically compatible vehicle and/or adjuvant.


4. (Currently Amended) The pharmaceutical composition according to claim 2, which contains ~~claim 3~~, wherein the compound of formula I is 11 β -fluoro-17 β -hydroxy-7 α -methyl-estr-4-en-3-one.

5. (Cancelled)

6. (Currently Amended)

The A male contraceptive combination

containing agent according to claim 5, wherein the compound of formula I is 11 β -fluoro-17 β -hydroxy-7 α -methyl-estr-4-en-3-one or a pharmaceutically acceptable salt thereof, and



7. (Currently Amended)

The male contraceptive combination agent

according to claim 6 claim 5, wherein the 11 β -fluoro-17 β -hydroxy-7 α -methyl-estr-4-en-3-one or a pharmaceutically acceptable salt thereof androgenic compound of formula I is formulated pharmaceutically such that it is suitable to be implanted in the body of a male user such that it the androgenic compound is released continuously as an extended release formulation to the user.

8. (Currently Amended)


The male contraceptive combination agent

according to claim 6 claim 5, wherein the 11 β -fluoro-17 β -hydroxy-7 α -methyl-estr-4-en-3-one or a pharmaceutically acceptable salt thereof androgenic compound of formula I is provided therein for oral administration.

9. (Currently Amended)


The male contraceptive combination agent

according to claim 6 claim 5, wherein the




gestagen therein is formulated pharmaceutically such that it is released to the body of the male user as an extended release formulation.

10. (Currently Amended) The male contraceptive combination agent according to claim 9, wherein the




gestagen is formulated such that it is suitable to be implanted in the body of a male user over an extended period, such that the gestagen is released continuously as an extended release formulation to the user.

11. (Currently Amended) The male contraceptive combination agent according to claim 9 ~~claim 10~~, wherein the



gestagen is formulated such that it is suitable for administration transdermally.

12. (Currently Amended) The male contraceptive combination agent according to claim 6 claim 5, wherein the



gestagen is formulated for oral administration.

13-16. (Cancelled)